Brain Cancer Clinical Trials in Seattle

Showing 21-40 of 70 trials

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

NCT01734512

This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.

Pediatric Recurrent Progressive Low-grade GliomasPediatric Progressive Low-grade Gliomas

University of California, San Francisco65 participantsStarted Dec 2012

Los Angeles, California, United States • Los Angeles, California, United States • Oakland, California, United States +15 more locations

COMPLETEDEARLY Phase 1< 1 mile

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

NCT01748149

This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E or BRAF Ins T mutation.

Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas

University of California, San Francisco40 participantsStarted Apr 2014

Los Angeles, California, United States • Los Angeles, California, United States • Oakland, California, United States +18 more locations

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas

Brain Cancer Trials in Other Cities

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Cancer Stem Cell High-Throughput Drug Screening Study

A Pilot RCT of the PRISM Intervention for AYAs With Cancer

Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)

Other Conditions in Seattle